Neutron Holdings

Neutron Therapeutics is a medical technology company specializing in the development of accelerator-based Boron Neutron Capture Therapy (BNCT) systems for the treatment of difficult-to-manage cancers. Its flagship platform, the nuBeam suite, is a compact, high-throughput neutron source designed for hospital installation, eliminating the historical requirement for nuclear reactors to perform BNCT. The therapy involves the administration of a boron-10 carrier drug that selectively accumulates in tumor cells, followed by irradiation with low-energy neutrons to trigger a localized nuclear reaction that destroys malignant cells with cellular precision. The company is currently engaged in clinical trials at major institutions, including Helsinki University Hospital, focusing on indications such as recurrent head and neck cancer and glioblastoma.